Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus TARKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus TARKA.
CARDENE vs TARKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Combination of trandolapril (angiotensin-converting enzyme inhibitor) and verapamil (calcium channel blocker). Trandolapril inhibits ACE, reducing angiotensin II production, leading to vasodilation and decreased aldosterone secretion. Verapamil blocks L-type calcium channels, causing coronary and peripheral vasodilation, and negative chronotropic/inotropic effects.
20-40 mg orally three times daily.
Tarka (trandolapril/verapamil) is available as fixed-dose combinations: 1 mg/180 mg, 2 mg/180 mg, 2 mg/240 mg, 4 mg/240 mg. For hypertension, initial dose is 1 mg/180 mg orally once daily; titrate based on blood pressure response, maximum dose 8 mg/480 mg per day.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Trandolaprilat terminal t1/2 16–24 h (prolonged in renal impairment, e.g., CrCl <30 mL/min ~36 h); verapamil t1/2 6–12 h (active metabolite norverapamil t1/2 ~12 h)
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: trandolaprilat 33% (unchanged 13%), trandolapril 10%; fecal: 66% (trandolaprilat 21%, trandolapril 33%); verapamil: renal 70% (16% unchanged), fecal 16%
Category C
Category C
Calcium Channel Blocker
ACE Inhibitor + Calcium Channel Blocker